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Abstract
Early observations from countries that have introduced rotavirus vaccination suggest that there may be indirect protection
for unvaccinated individuals, but it is unclear whether these benefits will extend to the long term. Transmission dynamic
models have attempted to quantify the indirect protection that might be expected from rotavirus vaccination in developed
countries, but results have varied. To better understand the magnitude and sources of variability in model projections, we
undertook a comparative analysis of transmission dynamic models for rotavirus. We fit five models to reported rotavirus
gastroenteritis (RVGE) data from England and Wales, and evaluated outcomes for short- and long-term vaccination effects.
All of our models reproduced the important features of rotavirus epidemics in England and Wales. Models predicted that
during the initial year after vaccine introduction, incidence of severe RVGE would be reduced 1.8–2.9 times more than
expected from the direct effects of the vaccine alone (28–50% at 90% coverage), but over a 5-year period following vaccine
introduction severe RVGE would be reduced only by 1.1–1.7 times more than expected from the direct effects (54–90% at
90% coverage). Projections for the long-term reduction of severe RVGE ranged from a 55% reduction at full coverage to
elimination with at least 80% coverage. Our models predicted short-term reductions in the incidence of RVGE that exceeded
estimates of the direct effects, consistent with observations from the United States and other countries. Some of the models
predicted that the short-term indirect benefits may be offset by a partial shifting of the burden of RVGE to older
unvaccinated individuals. Nonetheless, even when such a shift occurs, the overall reduction in severe RVGE is considerable.
Discrepancies among model predictions reflect uncertainties about age variation in the risk and reporting of RVGE, and the
duration of natural and vaccine-induced immunity, highlighting important questions for future research.
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Introduction
Rotavirus is the leading cause of severe diarrhea in children,
representing a major source of morbidity and mortality worldwide.
The recent development and licensing of two vaccines, Rotarix
(GlaxoSmithKline Biologicals; Rixensart, Belgium) and RotaTeq
(Merck & Co; Whitehouse Station, NJ), provide a novel means of
controlling rotavirus. Early evidence from developed countries
that have introduced rotavirus vaccination into their national
immunization program strongly supports the direct and indirect
benefits of vaccination [1,2,3,4,5,6]. However, the enormous
potential these vaccines hold for preventing morbidity and
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mortality from rotavirus-associated gastroenteritis (RVGE) has yet
to be fully realized as many countries, particularly those in high
mortality settings of Asia and Africa, have yet to implement
routine rotavirus immunization programs.
In response to the advent of rotavirus vaccines, there has been a
recent surge in the development of mathematical models for the
transmission dynamics of rotavirus [7,8,9,10,11,12,13]. Such
models are essential for understanding the full epidemiological
impact of vaccination, including the potential indirect effects, i.e.
‘‘herd protection’’ for vaccinated and unvaccinated individuals
resulting from reduced transmission of rotavirus in the community.
The models can assist in early decision-making and provide insight
into the potential cost-effectiveness of vaccination by projecting
vaccine-induced changes in the epidemiology of RVGE over time.
Models for the transmission dynamics of rotavirus are structured
based on studies of the natural history of infection and immunity
[14,15,16,17,18,19,20,21]. However, such data can have multiple
interpretations, and information linking individual-level data on
the course of infection to the between-person transmission of
rotavirus is lacking. These issues have led to variation in the
structure of mathematical models for rotavirus and differences in
the parameter estimates that are used to implement the models.
Although studies typically explore the sensitivity of model
outcomes to the input parameters, the sensitivity of outcomes to
variation in model structure is rarely addressed for the dynamics of
any infection [22,23,24,25,26], and has not previously been
explored for rotavirus.
Whereas some models predict that the reduction in RVGE due
to vaccination will exceed estimates derived only from the direct
effects of vaccination [8,11,12,13], other models predict that there
will be little or no long-term indirect effects of vaccination [7,9,10].
All of these outcomes have been evaluated on different time scales
using models calibrated to data from different countries. Given
these varied predictions, it is essential for policymakers to
understand the sources of uncertainty in the formulation and
parameterization of rotavirus models in order to have a sound
basis for evaluating the expected benefits of introducing rotavirus
vaccines into national immunization schedules. Public health
officials also need to understand the sources of uncertainty as they
assess the impact of new rotavirus vaccine programs and use
models to aid in the interpretation of post-introduction disease
dynamics, particularly when seasonality or age-patterns of disease
appear to change.
We brought together five groups that have previously developed
dynamic mathematical models for the transmission of rotavirus
[7,8,9,10,11,12,13]. We compared five model structures and their
statistical validation against epidemiological data. We adapted the
models by making common parameter assumptions where possible
(Table S1) and fitting to age-stratified reports of laboratory-
confirmed RVGE in England and Wales (E&W), taking advantage
of nationwide surveillance data collected for an extended period of
time which also included detailed information on age of cases, and
had been calibrated against community incidence (i.e. there is an
estimate of the reporting fraction, which incorporates the
likelihood that an ill person will present to a general practitioner,
be tested for rotavirus, and that a positive test will be reported to
the surveillance system) [27,28,29]. Furthermore, our evaluation
of the magnitude of the indirect effects of vaccination may be
useful in informing cost-effectiveness analyses and future evalua-
tions of whether to introduce rotavirus vaccines into the routine
immunization schedule in E&W. For each best-fit model, we
explored the impact of vaccination on both the short-term
dynamics and long-term levels of rotavirus incidence under a
variety of assumptions about vaccine-induced protection and
coverage. This approach provided a unique opportunity to
examine the range of model projections regarding the impact of
rotavirus vaccination under a variety of model structures.
Methods
The Models
The five models for the transmission dynamics of rotavirus we
explored follow an SIS- (susceptible-infectious-susceptible) or
SIRS-like (susceptible-infectious-recovered-susceptible) compart-
mental framework (Table 1). All the models assume that infants
are protected by maternal immunity at birth, which wanes after a
mean period of approximately 3 months (Table 2). Compartmen-
tal diagrams of the models can be found in the Supporting
Information (Figure S1). Fixed model parameters are described in
Table 2, while parameters estimated from fitting the models to the
E&W data are described in Table 3 (see Text S1).
Model A is based on Shim et al (2009) [12] and Atkins et al
(2012) [8] and follows an SIRS framework with two levels of
disease severity, one representing severe RVGE and the other mild
RVGE. These two levels of severity were assumed to have
different infectious periods and levels of infectiousness (Table 2).
Asymptomatic cases of rotavirus infection were assumed not to
play a role in transmission. Reported cases were assumed to
represent a proportion of the severe RVGE cases, whereas mild
cases were assumed to go unreported (Table 2). Following
infection, it was assumed that there is a period of temporary
immunity, after which individuals re-enter the fully susceptible
class. However, the risk of infection was assumed to vary with age,
and was estimated by fitting the model to the E&W data (Table 3).
After 5 years of age, it was assumed that the proportion of cases
with severe compared to mild RVGE declines; this parameter was
estimated by fitting to the data (Table 3).
Model B is based on Pitzer et al (2009) [10] and follows an
SIRS-like structure with different levels of susceptibility used to
represent the declining risk of infection following one, two or more
infections. The protection conferred by primary and secondary
infections against subsequent infection was parameterized based
on data from the Velazquez et al (1996) Mexico cohort study [17]
(Table 2). Primary, secondary, and subsequent infections were
assumed to have different durations and different levels of
infectiousness (Table 2). Only a proportion of primary and
secondary infections were assumed to develop severe RVGE, a
fraction of which are subsequently reported. The proportion of
cases developing severe RVGE was parameterized from the
Mexico cohort study data (Table 2); the reporting fraction was
estimated by fitting the model to the E&W data (Table 3).
Following infection, it was assumed that there is a period of
temporary complete immunity in which individuals cannot be
reinfected (Table 2). Afterwards, individuals become susceptible
again, but have partial immunity such that subsequent infections
occur at a reduced rate, as mentioned above. To account for a
possible increase in the risk of symptomatic infection in older age
groups, it was assumed that partial immunity may wane over time;
the rate of waning of partial immunity was estimated by fitting to
the E&W data (Table 3).
Model C is based on de Blasio et al (2010) [9] and follows a
structure similar to that of Model B. However, Model C also
allowed for a 1-day incubation or ‘‘exposed’’ period following
infection prior to the onset of infectiousness (Table 2). Thus, it
follows an SEIRS-like structure. In addition, the waning of partial
immunity to symptomatic infection among re-infected individuals
with more than two past infections was assumed to be age-
dependent rather than occurring at a constant rate (Table 3).
Rotavirus Model Comparison
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Table 1. Description of key features of the five models.
Model A Model B Model C Model D Model E
Risk of infection and
severity of RVGE depend
on age
Risk of infection and
severity depend on the
number of previous
infections
Risk of infection and
severity depends on age
and the number of
previous infections; short
delay between infection
and onset of infectiousness
Risk of infection and
severity depends on
the number of previous
infections
Following infection,
individuals develop
full immunity or become
susceptible again
Temporary immunity
following infection
Temporary immunity
following infection
Temporary immunity
following infection
No period of full
immunity following
infection
Probability of
developing full immunity
depends on the number
of previous infections
Severe and mild RVGE
are tracked separately
and vary in infectiousness;
asymptomatic infections
do not transmit
After 2 infections,
subsequent infections
are less infectious and
not reported
After 2 infections,
subsequent infections
are less infectious and
not reported
After 4 infections, all
individuals develop
full immunity (that
may wane)
After 4 infections, all
individuals develop full
immunity (that may
wane); asymptomatic
infections do not transmit
Only severe RVGE cases are
reported
Only severe RVGE cases
are reported
Only severe RVGE cases
are reported
Mild and severe RVGE
cases are reported;
reporting rate
depends on age
(,5 or $5 years old)
Mild and severe RVGE
cases are reported
doi:10.1371/journal.pone.0042320.t001
Table 2. Fixed parameter values for the five models.
Parameter Model A Model B Model C Model D Model E
Duration of maternal
immunity
13 weeks 13 weeks 13 weeks 13 weeks 13 weeks
Duration of incubation
period
NA NA 1 day NA NA
Duration of infectiousness
First infection 7 days (severe) 7 days 7 days 7 days 7 days
Subsequent infections 3.5 days (mild) 3.5 days 3.5 days 3.5 days 7 days
Relative risk of infection
following:
First infection NA 0.62 0.62 0.62 0.62
Second infection 0.37 0.37 0.37 0.37
Third infection 0.37 0.37 0.37 0.37
Proportion of infections
with any RVGE (severe
RVGE)
First infection 0.76 (0.24) for 0.47 (0.13) 0.47 (0.13) 0.47 (0.13) 0.47 (0.13)
Second infection ,5 yr olds 0.25 (0.03) 0.25 (0.03) 0.25 (0.03) 0.25 (0.03)
Third infection Estimated for $5 0.20 (0) 0.20 (0) 0.32 (0) 0.32 (0)
Fourth infection yr olds NA NA 0.20 (0) 0.20 (0)
Relative infectiousness
(compared to first infection)
Second infection 0.5 for mild vs severe
RVGE;
0.5 0.5 0.5 Only individuals
with any RVGE
Subsequent infections asymptomatic
infections
do not transmit
0.2 0.2 0.2 transmit (see above)
Duration of complete
immunity
1 year 1 year 1 year NA NA
Type of cases reported Severe RVGE Severe RVGE Severe RVGE Any RVGE Any RVGE
doi:10.1371/journal.pone.0042320.t002
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Model D is based on Van Effelterre et al (2009) [13] and follows
an SIS-like structure. It was assumed that there is a decreased risk
of reinfection following one, two or three infections (similar to
Models B and C) and full immunity following four infections, but
there was no temporary complete immunity following infection
(Table 2). Furthermore, the risk of infection was assumed to be
age-dependent (similar to Model A) and the full immunity gained
after four infections was allowed to wane over time. The age-
specific risk of infection and the rate of waning of immunity were
estimated by fitting the model to the E&W data (Table 3).
Primary, secondary, and subsequent infections were assumed to
have different durations and different levels of infectiousness
(Table 2). Reporting was assumed to reflect any (severe and mild)
RVGE rather than just severe cases. Again, a proportion of first,
second, third, and fourth infections were assumed to develop mild
and/or severe RVGE, in accordance with data derived from
Velazquez et al (1996) [17] (Table 2). The fraction of any RVGE
cases reported was assumed to differ between individuals ,5 years
of age and those $5 years of age, which were estimated by fitting
the model to the E&W data (Table 3).
Model E is based on Atchison et al. (2010) [7] and follows a
hybrid SIS-SIR-like structure. It was assumed that some individ-
uals develop long-term immunity following infection, whereas
others become susceptible to reinfection at the same rate as fully
susceptible individuals. Thus, natural immunity was assumed to be
‘‘all-or-nothing’’ as opposed to ‘‘leaky’’ [30,31]. The fraction of
individuals becoming immune or susceptible to reinfection, as well
as the proportion of infections developing mild and/or severe
RVGE, was parameterized based on data from Velazquez et al
(1996) [17] (Table 2). It was assumed that the duration of
infectiousness is the same for all infections, but that only
symptomatic RVGE cases are infectious (Table 2). Reporting
was assumed to reflect any RVGE cases (like Model D), with the
reporting fraction based on a study of national surveillance and
reporting practices in E&W [28]. Immunity to reinfection could
wane over time among older individuals, with the rate of waning
estimated by fitting the model to the E&W data (Table 3).
Model Fitting
We estimated several (non-fixed) model parameters and
statistically validated and compared our models by fitting each
model to age-stratified reports of laboratory-confirmed rotavirus
infection from England and Wales [27,28,29]. Data on the
number of rotavirus-positive specimens reported by diagnostic
laboratories to the Health Protection Agency from January 1999
to June 2009 were stratified by calendar week and age in the
following 19 age groups: 0–1 month, 2–3 months, 4–5 months, 6–
7 months, 8–9 months, 10–11 months, 12–13 months, 14–15
months, 16–17 months, 18–19 months, 20–21 months, 22–23
months, 2 years, 3 years, 4 years, 5–24 years, 25–44 years, 45–64
years, and $65 years old. We assumed that transmission-relevant
mixing reflects the self-reported number of physical contacts
among members of different age groups in E&W (see Text S1)
[32]; the probability of transmission given exposure to an
infectious contact was estimated for each model by fitting to the
E&W rotavirus data. Seasonality in the transmission rate was
modeled using a sinusoidal function, the parameters of which were
estimated by fitting to the E&W data (see Text S1). To ensure that
baseline demographic conditions were equivalent across models,
we assumed a constant population size and birth rate through time
(both before and after the introduction of the vaccine) equal to
Table 3. Parameters estimated by fitting models to data on laboratory-confirmed RVGE cases in England and Wales.
Parameter Symbol Model A Model B Model C Model D Model E
Duration of immunity
to symptomatic
infection
1/v NA* 280 years A = 7.31e-9,
B = 0.228{
833 years 201 years
Amplitude of
seasonality in
transmission
b 0.064 0.057 0.040 0.046 0.052
Seasonal offset Q 0.089 0.377 0.209 0.014 0.237
Age-specific risk
of infection
qi, for age
group i,
as specified
0.083 (,1 y), 0.065 (1 y),
0.017 (2 y), 0.006 (3 y),
0.003 (4–65 y),
0.025 ($65 y)
0.291 (all
age groups)
0.402 (all
age groups)
0.562 (,1 y),
0.718 (1 y),
0.344 (2 y),
0.144 (3 y),
0.077 (4 y),
0.068 ($5 y)
0.890 (all age
groups)
Proportion of cases
with severe RVGE
in $5 yr olds
di 0.015 NA NA NA NA
Reporting fraction r 0.064 0.122 0.123 0.024 (,5 y),
0.005 ($5 y)
Fixed at 0.029
Basic reproductive
number
R0 1.23 18.2 17.6 5.03 26.2
Number of parameters
estimated
k 10 5 6 12 4
Akaike information
criterion (AIC)
71,990 84,977 76,303 83,912 66,697
*NA=Not applicable.
{An exponential distribution was used to describe increasing probability for reported symptomatic infection with age. With probability p(a) = A*exp(a*B) exposed
individuals in ‘‘later infection’’ are moved to exposed group of second infection. The remaining 1-p(a) continues to the ‘‘later’’ infection group. The age a was chosen as
the midpoint of the various age groups.
doi:10.1371/journal.pone.0042320.t003
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estimates for E&W in 2008 (population size of 54.5 million and
birth rate of 13.0 per 1,000 population= 708,700 births per year).
Deaths occurred only upon exiting the last age group ($65 years
old), leading to an approximately square age distribution that is
roughly similar to the observed population pyramid [33].
We calculated the log-likelihood of the data under each model
by assuming that the reported number of weekly RVGE cases in
each age group was Poisson distributed with a mean equal to the
model-predicted number of cases (see Text S1 for details). The
best-fitting parameter set was that which maximized the log-
likelihood (log(L)) of the age-stratified time series for the given set
of estimated and fixed parameters. To compare across models, we
calculated the Akaike information criterion (AIC) as 2k – 2log(L),
where k is the number of estimated parameters (Table 3). Lower
AIC values indicate a better model fit.
Impact of vaccination
We incorporated vaccination into each of the best-fitting models
and explored both the short- and long-term effects of vaccination
under a variety of assumptions about vaccine coverage and
efficacy. Our analysis focused on model projections for the
incidence of severe RVGE (Vesikari score $11); results for any
RVGE are presented in Text S1 and Figure S3.
Most of the models assume the effect of vaccination is
comparable to natural immunity from rotavirus infection, as
observed in natural history studies, such that successive doses of
the vaccine confer immunity comparable to that conferred by one
or more natural infections. Thus, vaccination was assumed to
confer some protection against infection and stronger protection
against infectiousness and disease given infection. This approach
yields predicted vaccine efficacies against RVGE similar to those
measured during clinical trials conducted in developed countries
(see below) [34,35,36,37]. For Model A, however, a separate input
parameter was required for the vaccine efficacy, because risk of
infection was assumed to decline with age rather than with the
number of previous infections. We assumed the vaccine efficacy in
Model A was equal to that predicted under the other models (see
Text S1).
It is unclear whether successive doses of a vaccine confer
additional protection, as is observed with natural infections. To
address this uncertainty, we explored two possible scenarios: (1)
vaccination confers protection comparable to that conferred by
primary infection following the first dose administered at 2 months
of age (with further doses providing no additional benefit), and (2)
vaccination confers protection comparable to that following
primary infection when the first dose is given at 2 months of age
and additional protection comparable to that conferred by
secondary infection when the second dose is administered at 4
months of age. We assumed that 96% of individuals receiving each
dose of the vaccine seroconvert and therefore benefit from that
dose of the vaccine [38] (i.e. protection is ‘‘leaky-or-nothing’’ [30],
with 4% of individuals receiving no protection whatsoever).
Scenario 1 equates to a vaccine efficacy of 82% against severe
RVGE and 64% against any RVGE, whereas scenario 2 equates
to vaccine efficacies of 99% and 74% against severe and any
RVGE, respectively (see Text S1 for calculations). These values
represent the breadth of vaccine efficacy estimates derived from
clinical trials conducted in Europe and Latin America
[34,35,36,37].
In preliminary analyses, we also explored the effect of
vaccination assuming that protection is comparable to that
conferred by primary infection and only occurs after the second
vaccine dose at 4 months of age (weakest effect), or allowing for
additional vaccine-induced protection following each dose includ-
ing a third vaccine dose administered at 6 months of age (strongest
effect). However, model projections for the short- and long-term
impact of vaccination under these scenarios did not differ
substantially from those under scenarios 1 and 2, respectively.
For all models, we evaluated the short-term effect of vaccination
on the dynamics of rotavirus over a five-year period following the
introduction of the vaccine. For each scenario, we assumed that
the vaccine was introduced into the population prior to the start of
the rotavirus season in October (week 40) at a coverage level of
either 70% or 90% of all eligible infants; coverage was maintained
at a constant level following vaccine introduction. We examined
model projections for the incidence of severe RVGE and any
RVGE in children ,5 years of age (an age range in which 95% of
reported RVGE cases occur prior to vaccination) and in
individuals $5 years of age to examine a possible shift in the
burden of illness to older age groups following vaccine introduc-
tion.
We also examined the short-term percent reduction in the
cumulative incidence of severe RVGE cases predicted by the
models over one, two, and five years after the introduction of the
vaccine (evaluated starting from week 1 of the year following
vaccine introduction) and compared this to the direct effect of
vaccination.
The long-term effect of vaccination was measured by the
percent reduction in the mean incidence of severe or any RVGE
over the full range of vaccine coverage levels (0–100%) during a 10
year period beginning 10 years after vaccine introduction, i.e.
during years 10–19 post-introduction. Again, we compared this to
the direct effect of the vaccine.
The direct effect of vaccination y years after vaccine introduc-
tion was calculated as the product of the assumed vaccine efficacy,
the weekly proportion of vaccinated individuals in each age group,
and the weekly number of RVGE cases reported pre-vaccination
in that age group, summed over all age groups and weeks from
week 1 of the year following vaccine introduction to week 52 of
year y (see Text S1 for details). Thus, our calculation of the direct
effect assumes that vaccinated individuals are the only ones to
benefit from vaccination and are protected for life. The degree of
indirect protection was determined by subtracting the direct effect
from the overall reduction projected by the models.
Results
All the fitted models were qualitatively similar to the E&W
rotavirus data (Figure 1, Figure S2), reproducing the pattern of
strong winter seasonal epidemics occurring around week 9–13
each year (Figure 1A). The models also reproduced the age
distribution of cases, although they tended to over-estimate the
proportion of cases occurring in the youngest age groups (,6
months of age) and in either the 5–24 year (Models B and C) or
25–64 year (Models A, D, and E) age groups (Figure 1B).
Short-term impact of vaccination
The five models predicted a range of possible short-term
dynamics following vaccine introduction (Figure 2). We examined
the relative incidence of severe RVGE before and after
vaccination and normalized the results by dividing by the peak
pre-vaccination incidence. Under scenario 1 with vaccine cover-
age of 70%, the relative incidence of severe RVGE in children ,5
years old was reduced by 25% (Model E) to 37% (Model D) in the
first year following vaccine introduction, but the timing of the
rotavirus epidemic was similar to the pre-vaccination timing
(Figure 2A). The biggest discrepancies among the various model
projections emerged during the second year following vaccine
Rotavirus Model Comparison
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introduction. The peak in rotavirus incidence varied from week 19
(Model A) to week 36 (Model D). The peak incidence was reduced
by 41–50% in Models B and E and by 66–70% in Models A, C,
and D (Figure 2A,i), although differences in overall annual
incidence were less dramatic. During the third year, peak
incidence was reduced by 87–89% in Models C and D, but was
only reduced by 63–71% in Models A, B, and E. Under scenario
1, at 90% coverage, the discrepancy among projections of different
models was greater during the second and third year following
vaccine introduction. Model D predicted a two-year period of very
low incidence during which elimination of rotavirus from the
population would likely occur; Model C predicted a pattern of
biennial epidemics with incidence increasing through the summer
of year 2 (and future even years) and peaking early in year 3 (odd
years). In contrast, the other models predicted annual epidemics
(Figure 2A,ii). Similar discrepancies also occurred under scenario
2. Model D predicted a pattern of biennial epidemics at 70%
coverage and elimination of the rotavirus from the population at
90% coverage, whereas Models A–C and E predicted annual
epidemics at 70% coverage and potentially biennial epidemics at
90% coverage (Figure 2A,iii–iv).
The incidence of severe RVGE in individuals older than 5 years
exhibited similar timing to the incidence in children ,5 years of
age, but some of the models suggested that the relative incidence of
severe RVGE in older individuals could increase following vaccine
introduction (Figure 2B). The relative incidence of severe RVGE
was greatest under Model E, increasing greater than four-fold at
90% coverage under scenario 2 (Figure 2B,iv). Models B and C
also predicted an increase in the incidence of severe RVGE in this
age group, but the relative increase was less than two-fold under
these models.
The reduction in the cumulative incidence of severe RVGE
during the first year after vaccine introduction was similar across
the five models, particularly for the ,5 year old population where
most of the cases occur (Figure 3A). The models predicted a 25–
37% reduction in the number of severe RVGE cases during the
first year after vaccine introduction at 70% coverage when no
additional benefit from successive doses of the vaccine was
assumed (scenario 1); only a 13% reduction in incidence would
be expected from the direct effect of the vaccine alone. The
discrepancy among model projections was slightly greater at 90%
coverage, particularly when the second dose of the vaccine is
assumed to provide additional immunity (scenario 2). At 90%
coverage, a 34–50% reduction in severe RVGE was predicted by
the models, with a 19% reduction expected from the direct effect
of the vaccine. Thus, all of the models predicted considerable
short-term indirect protection evident from a 1.8- to 2.9-fold
greater than expected reduction in the incidence of severe RVGE
Figure 1. Fit of models to RVGE case reports from England and Wales. (A) Mean annual size and timing of rotavirus epidemics in individuals
(i) ,5 years of age and (ii) $5 years of age. The solid black line represents the mean number of RVGE cases per week. Dashed lines show the
minimum and maximum number of cases each week. Colored lines represent the fitted models: Model A (blue), Model B (yellow), Model C (green),
Model D (purple), Model E (red). (B) Age distribution of reported rotavirus cases (bars) and the fitted models (colored lines).
doi:10.1371/journal.pone.0042320.g001
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during the first year after vaccine introduction, compared to when
indirect effects are ignored.
However, differences in the level of indirect protection predicted
by the different models were accentuated when examining the
reduction in cumulative incidence of severe RVGE over 2 to 5
years following vaccine introduction (Figure 3B,C). Model D
consistently predicted the greatest reductions in the cumulative
incidence of severe RVGE, which were substantially greater than
the reduction in incidence due exclusively to the direct effect of the
vaccine for both the ,5 year and $5 year old populations. Model
E predicted similar reductions in the incidence of severe RVGE
occurring in children ,5 years of age as compared to Model D
(particularly at 70% coverage), but it predicted a substantial
increase in the relative incidence of severe RVGE occurring in
individuals $5 years old, which was not predicted by the other
models. Models A–C predicted more modest reductions in the
cumulative incidence of severe RVGE 2 to 5 years after vaccine
introduction. There was little or no indirect protection against
severe RVGE predicted by Model A when considering the
cumulative incidence of severe RVGE in all age groups over the 5
Figure 2. Short-term dynamics of rotavirus epidemics in the first 5 years after vaccine introduction. (A) Weekly incidence of severe RVGE
predicted for individuals ,5 years of age, scaled by peak pre-vaccination incidence, for the following scenarios: (i) 70% coverage with a vaccine that
confers immunity comparable to primary infection following first dose at 2 months of age (82% efficacy) (scenario 1); (ii) 90% coverage under scenario
1; (iii) 70% coverage with a vaccine that confers immunity comparable to one natural infection following each dose at 2 and 4 months of age (99%
efficacy) (scenario 2); and (iv) 90% coverage under scenario 2. (B) Incidence of severe RVGE predicted in individuals $5 years of age under coverage
scenarios (i–iv) for Model A (blue), Model B (yellow), and Model C (green), Model D (purple), Model E (red).
doi:10.1371/journal.pone.0042320.g002
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year period after vaccine introduction. Model B also predicted
minimal levels of indirect protection over the 5 years, particularly
at 70% coverage.
Long-term impact of vaccination
With a vaccine efficacy of 82% against severe RVGE assumed
under scenario 1, the predicted effects of vaccination range from a
long-term reduction in the incidence of severe RVGE that is
slightly less than would be expected from the direct effect of the
vaccine alone to indirect protection that could eliminate rotavirus
from the population at 100% coverage. Four of the five models,
however, predicted that the vaccine would not provide long-term
indirect protection in the population as a whole (Figure 4A,iii).
Models B, C, and E show a reduction in the incidence of severe
RVGE among children,5 years of age that exceeds that expected
from the direct effect of the vaccine alone (Figure 4A,i), suggesting
there may be some indirect protection for this age group,
particularly at high coverage levels. However, this indirect
protection was partially offset by an increase in the incidence of
severe RVGE among individuals $5 years of age (Figure 4A,ii).
Thus, Models B, C, and E suggest that vaccination will only delay
the time to infection and disease in individuals not protected by the
vaccine rather than preventing severe RVGE among these
individuals. However, the overall reduction in severe RVGE
predicted across all age groups due to the direct effect of
vaccination is still substantial. Models A and D predicted a
reduction in the incidence of severe RVGE among individuals $5
years old that indicates considerable indirect protection in this age
group (Figure 4A,ii). However, for Model A, there was a less
substantial reduction in incidence than expected based on the
direct effects among children ,5 years of age (Figure 4A,i).
The long-term impact of vaccination predicted by the models
under scenario 2 was similar to that under scenario 1. However,
because the efficacy of the vaccine against severe RVGE is
assumed to be 99% under scenario 2 compared to 82% under
scenario 1, the reduction in the incidence of severe RVGE due to
the direct effect of vaccination is expected to be greater (Figure 4B).
Again, most of the models predicted there would be little or no
additional reduction in the incidence of severe RVGE (i.e. in excess
of the direct effect) in the population as a whole, although Models
B and C predicted there may be some indirect protection at
coverage levels exceeding 90% (Figure 4B,iii). Elimination of
rotavirus from the population was predicted to be possible under
Figure 3. Short-term impact of vaccination on the cumulative incidence of severe RVGE predicted by the models. The relative
cumulative incidence of severe RVGE after versus before vaccine introduction in individuals (i) ,5 years of age, (ii) $5 years of age, and (iii) all age
groups over the first (A) 1 year, (B) 2 years, and (C) 5 years after vaccine introduction are presented for scenarios 1 and 2 at 70% and 90% coverage.
Black bars represent the direct effects of vaccination (see Text S1), while the colored bars represent the model projections: Model A (blue), Model B
(yellow), Model C (green), Model D (purple), Model E (red). The y-axis is truncated at 1.1; where the bars exceed this threshold, i.e. for Model E in panel
(C,ii), the red numbers indicate the relative cumulative incidence.
doi:10.1371/journal.pone.0042320.g003
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Model D when at least 80% of eligible infants were vaccinated
with at least two doses of the vaccine (Figure 4B,iii). Model A,
however, predicted only a 78% reduction in the incidence of
severe RVGE at 100% coverage; this was due to a less substantial
reduction in incidence than expected among ,5 year olds
(Figure 4B,i). Model E predicted a large increase in the relative
incidence of severe RVGE among individuals $5 years old
(Figure 4B,ii). Models B and C predicted a smaller increase in the
relative incidence of severe RVGE among older individuals at
coverage levels ,90%, but a decline in incidence among $5 year
olds at 100% coverage (Figure 4B,ii). However, all models
predicted substantial declines in severe RVGE and all RVGE
(Figure S3) for the population as a whole.
Discussion
Our results reveal several interesting discrepant findings among
the model projections for the short- and long-term impact of
vaccination that shed light on some of the important questions
about rotavirus epidemiology. Direct comparison of differences in
model structure and estimated parameters allows us to understand
the reasons for the variation in model projections. Fundamentally,
these variations in model projections reflect gaps in our
understanding of the mechanisms of rotavirus infection, natural
immunity, epidemiology, and the biological nature of vaccine
protection. Much of the uncertainty regarding the expected
indirect effects of vaccination in the literature stems from different
model assumptions for why severe RVGE is rare among older
children and adults, and to what extent natural and vaccine-
induced immunity wanes over time.
The five models we analyzed reproduce the seasonality and age
distribution of rotavirus incidence in E&W, providing an
important source of model validation. We compared the statistical
fit of these models to week- and age-stratified laboratory reports of
confirmed rotavirus cases from E&W, and found that all five
models had AIC values between 66,697 and 84,997. Given the
large number of data points we attempted to fit (547 weeks619 age
groups = 10,393 data points), the relatively large AIC values and
the variation among models with different numbers of estimated
parameters is not surprising. Model E provided the best fit to the
pre-vaccination E&W RVGE reports, but the relative ranking of
models based on AIC should be interpreted cautiously when
extrapolating to the ability of the models to predict the impact of
vaccination. Furthermore, we only explored a single set of fixed
parameters and fit to a single data set; there is additional
uncertainty regarding the parameter values that was not account-
ed for in our analysis, and which would presumably affect the fit
differently for different models.
The models make different assumptions to explain why most
RVGE cases occur among children ,5 years of age (Table 1).
Both Models A and D allow for the risk of infection and/or
reporting to vary by age, and both models find that older
individuals are less likely to be infected with rotavirus than
younger individuals given equal levels of exposure (except among
$65 year olds in Model A) (Table 3). These models are
characterized by lower estimated values of the basic reproductive
number R0 (quantifying the transmission potential of rotavirus),
suggesting that the high incidence of rotavirus infection in the
population is due to the repeated infection of individuals
throughout their lifetime rather than being due to the large
number of individuals who can be infected by a single individual
with a primary infection. However, Models A and D differ in that
Model A assumes that individuals$5 years of age are less prone to
severe RVGE than those ,5 years of age and therefore tend to be
less infectious, whereas Model D assumes that severe infections
occur in older individuals but tend to be under-reported at a
Figure 4. Long-term impact of vaccination on the incidence of severe RVGE predicted by the models. The reduction in the incidence of
severe RVGE during a 10-year period beginning 10 years after vaccine introduction, as compared to the mean pre-vaccination incidence, is plotted for
coverage levels from 0 to 100%. The panels represent the reduction in incidence of severe RVGE under (A) scenario 1: vaccination is assumed to
confer immunity comparable to primary infection following the first dose at 2 months of age (82% efficacy), and (B) scenario 2: vaccination is
assumed to confer immunity comparable to one natural infection following each dose at 2 and 4 months of age (99% efficacy), for (i),5 years of age,
(ii) $5 years of age, and (iii) all age groups. Black dashed lines represent the direct effect of vaccination (see Text S1), while solid colored lines
represent the model projections: Model A (blue), Model B (yellow), Model C (green), Model D (purple), Model E (red).
doi:10.1371/journal.pone.0042320.g004
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higher rate. Furthermore, Model A assumes that immunity
following natural infection and vaccination is not long-lasting
and that the decline in the proportion of cases in older age groups
is entirely due to age-specific differences in the risk of infection and
disease. Model D assumes that immunity gained through repeated
natural infections partially accounts for the greater concentration
of RVGE in younger individuals. While Model A does not track
asymptomatic infections and assumes they play no role in
transmission, Model D does take into account possible transmis-
sion from such infections. Together, these differences help explain
why the R0 for Model D is slightly greater than the R0 for Model
A.
Models B, C, and E are similar to Model D in that they also
assume the progressive build-up of natural immunity to both
infection and symptoms of infection explains the greater concen-
tration of RVGE in children ,5 years of age. Immunity is
assumed to wane on a time scale that does not affect the ,5 year
old population (Table 3). Unlike Model D, however, these models
do not allow the rate of reporting of RVGE to differ between the
,5 years old and $5 years old age groups. Thus, the estimated
values of R0 for these models tend to be higher, suggesting a higher
incidence rate of infection and younger age of first infection with
rotavirus. As a result, there should be a greater correlation
between the age distribution of reported RVGE cases and the
RVGE cases responsible for the majority of rotavirus transmission
predicted by Models B, C, and E. In contrast, Model D implicitly
assumes that unreported cases of RVGE in older children and
adults play an important role in transmission; paradoxically, this
model projects stronger indirect protection because there are fewer
overall infections among older individuals in Model D than in
Models B, C, and E. In essence, Models A and D place more
emphasis on adults in the transmission process compared with
Models B, C, and E.
Part of the difficulty in deciding which model best represents the
underlying epidemiology of rotavirus infection is lack of knowledge
about the reporting pyramid for rotavirus. In other words, what
fraction of rotavirus infections are symptomatic, what fraction of
symptomatic infections present to the healthcare system, and what
fraction of those presenting get properly diagnosed as rotavirus? A
few studies have attempted to elucidate the reporting pyramid for
rotavirus infections in E&W, but they were underpowered to
understand the reporting fraction in adults, how reporting varies
over time, and how it correlates with the severity of symptoms
[27,28,29].
The similarities and differences in model structure are reflected
in the projections that each model yields for the indirect protection
conferred by vaccination. During the first 5 years after vaccine
introduction, the reduction in the cumulative incidence of severe
RVGE predicted by each model was similar for children ,5 years
of age and for the overall population. However, it is more difficult
to predict the pattern of epidemics following the introduction of
vaccination, as suggested by the different epidemic trajectories
predicted by each model. Furthermore, none of the models
account for additional complexities such as the interaction among
different genotypes of rotavirus, or environmental or local effects.
All of the models suggest that the post-vaccination timing of
rotavirus activity can vary considerably, with possible peaks
occurring in the summer and/or fall as opposed to the typical pre-
vaccination peaks occurring in winter/spring. This is consistent
with the relatively low amplitude of seasonal forcing (4.3–6.4%)
estimated for each model, which suggests that environmental
factors such as temperature or humidity only have a small effect on
the transmission rate, and that the large RVGE epidemics evident
in E&W primarily result from the dynamic interaction between
susceptible and infectious individuals [10,39]. By altering the rate
at which fully susceptible infants enter the population, vaccination
can lead to significant changes in the timing of rotavirus activity;
thus, models of the transmission dynamics of rotavirus can aid in
our understanding of the observed incidence patterns
[3,5,40,41,42].
Model projections suggest the short-term reduction in the
incidence of reported RVGE during the first five years after
vaccine introduction will exceed estimates that account only for
the direct effects of vaccination. This is supported by recent
observations of the early impact of vaccination in countries that
have introduced routine immunization, where 22–68% decreases
in the incidence of RVGE have been reported in age groups not
eligible to receive the vaccine [1,2,3,4,6], including older children
and adults [43,44]. At three sentinel sites in the US, the overall
incidence of hospitalization for RVGE among children 6–11
months of age was reduced by 87% in 2008, when coverage
among this age group was 77%; but in 2009 the RVGE
hospitalization rate among ,3 year olds was similar to that
expected based on coverage and vaccine effectiveness estimates
[45]. Models B, C, and E predict that the indirect benefits of
vaccination during the short term may not extend to the long
term, as the burden of RVGE may shift to older age groups.
Beginning in the second year after vaccine introduction and
continuing to the long term, model projections differ considerably
for the $5 year old population.
All of the models predict that vaccination will lead to a delay in
the average age of first infection with rotavirus and a decrease in
the number of infections experienced by a single individual during
his/her lifetime (results not shown). For Models B, C, and E which
assume that the severity of RVGE is associated only with the
number of previous infections, the delay in the time to infection
may shift some of the burden of severe RVGE to older individuals,
because first and second infections may be more likely to occur
after 5 years of age. If infections tend to be less severe and/or less
likely to be reported in the $5 year old age group than in the ,5
year old group, as estimated by Models A and D, the delay in the
time to infection is not predicted to increase the burden of RVGE
in the $5 year old age group. Furthermore, the decrease in the
overall number of infections experienced by individuals during
their lifetime could translate into a decrease in the number of
severe RVGE cases among older individuals, particularly if the
lifetime number of infections predicted by the model is relatively
small.
Whether or not vaccination provides long-term indirect
protection against severe RVGE in children ,5 years of age
depends on whether vaccine-induced immunity wanes completely
after 1 year, or if vaccinated infants remain at reduced risk of
RVGE for a prolonged period of time. The discrepancy in results
between Model A, which predicts the smallest reduction in severe
RVGE, and Model D, which predicts that elimination of RVGE is
possible under some scenarios, is due primarily to the different
assumptions made regarding the duration of immunity. If one
makes the alternative assumption in Model A that vaccine-induced
immunity lasts at least 3 years, then in this case Model A also
predicts that rotavirus could be eliminated at high coverage rates
[8]. Models B and C assume that the effect of vaccination may
wane partially after 1 year, but that vaccine-induced immunity
does not wane completely, whereas Model E assumes that long-
lasting immunity is only generated in some individuals. Deter-
mining if vaccine-induced immunity wanes over time, how waning
occurs, and how it differs across populations, is an important
avenue for future research.
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An important limitation of this study is that we do not
comprehensively explore the influences of parameter uncertainty.
Key uncertainties in our fixed parameter assumptions for rotavirus
include the duration of natural and vaccine-induced immunity,
protection conferred by previous infection(s), and relative infec-
tiousness of primary and subsequent symptomatic and asymptom-
atic) infections. Further work is needed to characterize and explore
the impact of this parameter uncertainty [46], while epidemiologic
studies are needed to obtain better estimates of unknown
parameters.
Conclusions
Overall, the comparison of these different models of rotavirus
transmission and vaccination allowed us to examine the impact of
structural uncertainty on the robustness of model projections, as
well as identify key gaps in our understanding of rotavirus
epidemiology. The models we compared suggest vaccination will
lead to a 64–100% reduction in the incidence of severe RVGE
and a 55–100% reduction in any RVGE at full coverage 10–20
years following vaccine introduction if vaccination confers
protection comparable to a single natural infection (Figure 4,
Figure S3). Similarly, vaccination will result in a 78–100%
reduction in severe RVGE and a 70–100% reduction in any
RVGE if a second dose of vaccine confers additional protection.
How the reduction in the incidence of severe and any RVGE
translates to fewer cases of reported RVGE will depend on
whether reporting reflects only cases of severe RVGE or both mild
and severe RVGE. Indirect protection against RVGE apparent in
the first few years after vaccine introduction may or may not
extend to the long term. Whether it is possible to eliminate
rotavirus infection from the population depends critically on the
transmissibility of primary infections (as indicated by the estimated
R0 of the best-fit models), what fraction of cases goes unreported,
and whether immunity wanes over time.
Our comparative analysis of the model projections for the
indirect effects of vaccination identified three key questions that
should be addressed to improve the accuracy of model predictions:
N What is the role of adults in rotavirus transmission?
Infection with rotavirus later in life is typically asymptomatic
and/or unreported, but infected individuals could be trans-
mitting rotavirus to others. The models we explored differed in
the emphasis placed on transmission from older children and
adults, which could account for some of the differences in
projections of the long-term impact of vaccination.
N What is the effect of multiple vaccine doses on protection?
Vaccination appears to confer immunity similar to that of
natural infection, but it is unclear whether multiple doses of the
vaccine yield an added benefit. We explored a variety of
different assumptions regarding the impact of multiple vaccine
doses, and found that the indirect benefits of vaccination may
be greater if each dose confers immunity comparable to an
additional natural infection. Understanding whether additional
doses of vaccine provide additional protection could lead to
new dosing schedules for developing countries, where vaccine
efficacy is lower.
N Does vaccine-induced immunity wane over time? If so,
what is the nature of this waning of immunity, i.e. is it
complete or incomplete? The models we explored make
different assumptions about the possible waning of immunity,
from complete waning of vaccine-induced immunity to no
waning of immunity. Age-specific estimates of vaccine efficacy
and case-control studies of vaccine effectiveness during the
second year of life suggest that there may be some waning of
vaccine-induced immunity [34,35,36,37], particularly in
developing country settings [47,48,49,50], but interpretation
of this data is complicated.
Experimental studies of rotavirus pathogenesis, carefully
designed epidemiologic studies, and stronger statistical links
between data and models will lead to better-informed model
assumptions and help to discriminate among models. In addition,
further validation and fitting of transmission dynamic models to
post-vaccination data from different countries will help to refine
model parameter estimates and improve projections of the long-
term impact of vaccination.
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Figure S3 Long-term impact of vaccination on the
incidence of any RVGE predicted by the models. The
reduction in the incidence of any RVGE during a 10-year period
beginning 10 years after vaccine introduction, as compared to the
mean pre-vaccination incidence, is plotted for coverage levels from
0 to 100%. The panels represent the reduction in incidence of any
RVGE under (A) scenario 1: vaccination is assumed to confer
immunity comparable to primary infection following the first dose
at 2 months of age (64% efficacy), and (B) scenario 2: vaccination is
assumed to confer immunity comparable to one natural infection
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